spacer
home > ebr > winter 2019 > unlocking the power of data
PUBLICATIONS
European Biopharmaceutical Review

Unlocking the Power of Data

Communicating with tens or hundreds of collections individually on a global scale has been stated as one of the biggest bottlenecks in seeking data and samples for pharmaceutical research. Academic research groups and industry alike demand an ecosystem that facilitates the sharing of data in a secure environment.

A global trend of rapidly aging populations, combined with a declining birth rate, as well as a rising number of rare diseases without effective treatments, has created a pressing need for collaboration in the healthcare and research spaces to make advances that will help mitigate this shift (1). Additionally, genetic data production and integration into healthcare have exponentially increased with the rise of new technologies and consumer interest. Although these developments hold much promise, they pose significant challenges in dealing with the sheer volumes of data produced, as well as applying it to make conclusions that address some of the world’s largest current healthcare challenges. Thus, the urgency for more open data sharing across institutions is becoming apparent because scientists require access to unique datasets if they are to realise the promise that personalised healthcare may provide.

This opens the door for a global network that can guarantee a confidential and secure environment for biobanks to share their anonymised data with pharma researchers who seek suitable patient cohorts within validated data clouds on a global scale. Such a global ecosystem, presented in this article along with a description of the changing healthcare landscape, exists so that researchers can efficiently search for specific cohorts of patients for population research and rare tumours.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Timo Kanninen is Chief Architect and founder of BC Platforms and has been the visionary behind the company’s main products. He has a wealth of experience in software development, genetic epidemiology, statistical genetics, and clinical statistics. Previously, Timo was the founder, CEO, and Chief Technology Officer of Statwell Oy, which provided statistical consultation for the pharma industry and academic medical researchers and was merged into BC Platforms in 2002. He studied information technology in production and statistics at Helsinki University of Technology and Helsinki University, Finland, and has co-authored many articles in high level scientific journals.
spacer
Timo Kanninen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement